Yahoo · Nov 6, 2026
3 Reasons Growth Investors Will Love Idexx (IDXX)
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

NYSE · IDXX
Healthcare · Medical - Diagnostics & Research
$698.47
Down-$8.82 (-1.26%)
Updated Nov 20, 2026, 1:51 AM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · IDXX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 18, 2026
IDXX closed at $698.47 after 20 trading sessions, up 23.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 18, 2026 | $684.64 | $704.85 | $683.72 | $698.47 | 373.71K |
| Nov 17, 2026 | $701.14 | $706.76 | $687.715 | $690.24 | 400.85K |
| Nov 16, 2026 | $705.00 | $713.105 | $698.68 | $700.65 | 491.06K |
| Nov 13, 2026 | $710.24 | $711.2289 | $702.53 | $704.23 | 392.45K |
| Nov 12, 2026 | $711.68 | $712.88 | $696.715 | $698.02 | 487.64K |
| Nov 11, 2026 | $688.04 | $703.84 | $680.00 | $702.59 | 423.32K |
| Nov 10, 2026 | $700.00 | $700.00 | $682.58 | $696.64 | 463.97K |
| Nov 9, 2026 | $682.35 | $709.26 | $680.89 | $706.65 | 703.73K |
| Nov 6, 2026 | $652.12 | $680.57 | $650.00 | $676.04 | 589.07K |
| Nov 5, 2026 | $702.00 | $704.03 | $664.81 | $670.71 | 873.28K |
| Nov 4, 2026 | $686.23 | $713.74 | $681.70 | $698.55 | 1.4M |
| Nov 3, 2026 | $662.26 | $681.495 | $655.515 | $672.04 | 1.19M |
| Nov 2, 2026 | $625.00 | $673.19 | $620.20 | $671.64 | 1.98M |
| Oct 30, 2026 | $583.75 | $586.00 | $540.61 | $551.21 | 1.17M |
| Oct 29, 2026 | $570.17 | $576.17 | $568.01 | $575.98 | 479.54K |
| Oct 28, 2026 | $556.78 | $567.77 | $555.2084 | $562.91 | 351.84K |
| Oct 27, 2026 | $563.23 | $567.545 | $559.0301 | $561.25 | 488.99K |
| Oct 26, 2026 | $564.23 | $571.75 | $557.94 | $570.21 | 528.16K |
| Oct 23, 2026 | $564.80 | $569.555 | $558.29 | $560.38 | 398.28K |
| Oct 22, 2026 | $562.01 | $568.67 | $558.39 | $566.76 | 430.12K |
The latest Smart Investors Daily articles mentioning IDXX.
Company
Market Activity
Research & News
IDXX research
Company profile and research snapshot.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2026 | UBS | Neutral | — |
| Nov 3, 2026 | Morgan Stanley | Overweight | — |
| Oct 27, 2026 | UBS | Neutral | — |
| Oct 16, 2026 | JP Morgan | Overweight | — |
| Oct 12, 2026 | Keybanc | Sector Weight | — |
No generated briefing is available yet.
Yahoo · Nov 6, 2026
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Benzinga · Nov 6, 2026
On November 5, a recent SEC filing unveiled that Michael Lane, Executive Vice President at IDEXX Laboratories (NASDAQ:IDXX) made an insider sell. What Happened: Lane's recent move involves selling 3,978 shares of
Benzinga · Nov 6, 2026
A substantial insider sell was reported on November 5, by Daniel M Junius, Board Member at IDEXX Laboratories (NASDAQ:IDXX), based on the recent SEC filing. What Happened: Junius's recent move involves selling 1,200
Benzinga · Nov 6, 2026
Sharon E Underberg, EVP at IDEXX Laboratories (NASDAQ:IDXX), reported a large exercise of company stock options on November 5, according to a new SEC filing. What Happened: Underberg, EVP at IDEXX Laboratories,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning IDXX.